Victoria AdolphusA groundbreaking clinical trial published in the New England Journal of Medicine reveals that immunotherapy significantly improves survival rates for advanced Hodgkin lymphoma, achieving a remarkable 92% survival rate over two years.
Key Findings:
- Immunotherapy combination therapy boosts survival rate to 92%, compared to 83% with standard care.
- Reduced long-term side effects, such as secondary cancers, cardiovascular, and pulmonary conditions.
- Innovative treatment activates immune system to target cancer cells.
- Trial designed to be highly inclusive, with participants as young as 12 and older than 60.
Expert Insights:
“We will see many fewer breast cancers, infertility issues, and heart diseases in patients treated with this immunotherapy.” – Jonathan Friedberg, MD, MMSc, Wilmot Cancer Institute Director
Trial Details:
- Phase 3 trial, S1826, enrolled nearly 1,000 patients across hundreds of cancer clinics and academic institutions.
- Patients received either standard therapy (chemotherapy and brentuximab vedotin) or immunotherapy combination (chemotherapy and nivolumab).
- Two-year follow-up showed 92% survival rate and no disease progression in immunotherapy group.
Implications:
- Potential new standard of care for advanced Hodgkin lymphoma.
- FDA approval anticipated.
- Model for future studies combining young and older patients.
- Reduced long-term side effects for pediatric patients.
Reference:
Friedberg et al. (2024). Nivolumab plus chemotherapy versus brentuximab vedotin plus chemotherapy in patients with newly diagnosed advanced Hodgkin lymphoma: A randomized phase 3 trial. New England Journal of Medicine.
Share Your Thoughts:
How will this immunotherapy breakthrough impact the treatment landscape for Hodgkin lymphoma?
